摘要
新生血管生成在肿瘤的发生、发展及转移中起重要作用,且抗血管生成治疗取得了令人满意的效果。抗血管生成药物的研究得到人们的关注。反应停在20世纪50年代曾作为镇静药、止吐药使用,因其有很强的致畸作用而被市场淘汰,后发现其有免疫调节作用被用于治疗麻风、红斑狼疮、宿主抗移植物排斥反应等。随后的研究认为,其致畸作用可能与抗血管生成有关,从而用于治疗实体瘤及血液系统肿瘤。本文就反应停的抗肿瘤作用研究进展作一综述。
Angiogenasis has an important role during the occurrence, development and metastasis of tumor. Antiangiogenic therapy has achieved satisfactory effects. The research of drugs about antiangiogenesis have been noted. Thalidomide was used as a sedative and antiemetie in the 1950s,then removed from markets for its severe side effects of teratogenasis. Its immunoloregulation effects was then discovered, which was used in the therapy of leprosy, erythematoans lupus and graft-versus-host reaction. Subsequent researches showed that its teratogenesis was possibly related to its antiangiogenesis,so it was used in the therapy of solid tumors and malignant hematological di sceses. This article reviews thalidomide about its anti-tumor effect..
出处
《医学综述》
2007年第3期200-202,共3页
Medical Recapitulate
关键词
反应停
血管新生
肿瘤
Thalidomide
Angiogenesis
Neoplasm
